Pharma in silica
Early-stage nano-oncology company developing silica-based nanoparticle drug-delivery systems intended to concentrate cytotoxic agents in tumors, reduce systemic toxicity, and advance candidates from preclinical studies toward IND/CTA and Phase Ib/IIa clinical evaluation. The organization emphasizes silica chemistry, translational PK/PD, CMC/process development, and partnership/licensing with pharmas.
Industries
Nr. of Employees
small (1-50)
Pharma in silica
Patents
Products
Chemotherapy nanocarrier candidate for non-small-cell lung carcinoma (NSCLC)
Silica-based nanoparticle formulation designed to load cytotoxic agents, circulate extensively, target tumors, and release payloads in the tumor environment; intended as the beachhead clinical candidate for NSCLC.
Nano-oncology prototype pipeline
Development of multiple silica-nanoparticle prototypes for oncology indications intended to generate additional licensing or development opportunities.
OpPacli
A beachhead product-candidate utilizing a proprietary silica nanocarrier to deliver cytotoxic agents specifically to tumors for the treatment of non-small-cell lung carcinoma (NSCLC).
Chemotherapy nanocarrier candidate for non-small-cell lung carcinoma (NSCLC)
Silica-based nanoparticle formulation designed to load cytotoxic agents, circulate extensively, target tumors, and release payloads in the tumor environment; intended as the beachhead clinical candidate for NSCLC.
Nano-oncology prototype pipeline
Development of multiple silica-nanoparticle prototypes for oncology indications intended to generate additional licensing or development opportunities.
OpPacli
A beachhead product-candidate utilizing a proprietary silica nanocarrier to deliver cytotoxic agents specifically to tumors for the treatment of non-small-cell lung carcinoma (NSCLC).
Services
Negotiation and execution of licensing and co-development agreements with pharma partners for silica nanocarrier product candidates.
Preclinical program execution including in vivo proof-of-concept and studies to support regulatory submissions (IND/CTA).
CMC and process development activities aimed at translation of silica nanoparticle formulations toward scalable manufacturing and industrialization (DMO planning).
Negotiation and execution of licensing and co-development agreements with pharma partners for silica nanocarrier product candidates.
Preclinical program execution including in vivo proof-of-concept and studies to support regulatory submissions (IND/CTA).
CMC and process development activities aimed at translation of silica nanoparticle formulations toward scalable manufacturing and industrialization (DMO planning).
Expertise Areas
- Nano-oncology drug delivery
- Silica chemistry and porous nanoparticle design
- Preclinical in vivo proof-of-concept studies
- PK/PD and translational science
Key Technologies
- Silica-based nanoparticles
- Nanoporous drug entrapment matrices
- Surface functionalization / stealth coatings
- Tumor-responsive drug release mechanisms
News & Updates
Initiated a multi-tranche US$10M seed round (Q2 2026) to fund IND/CTA enabling activities, Phase Ib/IIa study, and prototype development.
Initiated a multi-tranche US$10M seed round (Q2 2026) to fund IND/CTA enabling activities, Phase Ib/IIa study, and prototype development.